-- i remember someone asking about GERN and how they were doing lately... looks like the telomere patents are starting to pay off...
Geron Surges on Cancer Patent
Article Link
Biopharmaceutical company Geron's (GERN:Nasdaq - news - commentary - research - analysis) stock surged about 14% after the company said it was issued a U.S. patent for its cancer-destroying therapy, telomerase-based cancer immunotherapy.
By early afternoon, shares of Geron were up 57 cents to $4.42 on the Nasdaq.
The therapy, currently in Phase 1 human clinical trials, uses telomerase, an enzyme that is abnormally activated when tumors progress, to prepare a patient's immune system. Telomerase activation helps cancer cells resist cell death, which allows cells to grow and resist cytotoxic drugs. Geron's immunotherapy method works by telling the immune system to attack cells that contain telomerase.